Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen

Next Previous
X
Search
Trial Profile

Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birch pollen allergy immunotherapy-Anergis (Primary)
  • Indications Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Anergis

    • Most Recent Events

    • 07 Jun 2016 Results will be presented at the 35th European Academy of Allergy and Clinical Immunology (EAACI) Congress, according to an Anergis media release.
    • 07 Jun 2016 Results published in an Anergis media release.
    • 07 Jun 2016 Detailed results published in the Journal of Allergy and Clinical Immunology, according to an Anergis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top